<DOC>
	<DOCNO>NCT00251303</DOCNO>
	<brief_summary>This study examine effectiveness riluzole treat Obsessive-Compulsive Disorder Youth , Including Autism Spectrum Disorders .</brief_summary>
	<brief_title>Riluzole Treat Child Adolescent Obsessive-Compulsive Disorder With Without Autism Spectrum Disorders</brief_title>
	<detailed_description>Obsessive-Compulsive Disorder ( OCD ) chronic psychiatric disorder characterize presence intrusive unwanted obsessional thought image compulsive behavior . Its presentation childhood similar see adulthood , except child sometimes lack insight senselessness thought behavior . Although many patient benefit treatment selective serotonin reuptake inhibitor ( SSRIs ) , significant proportion limit response medication . Cognitive behavioral therapy ( CBT ) may also effective OCD , alone combination SSRIs , shortage qualify therapist , many patient family participate effectively therapy . There press need , , development alternative , novel treatment pediatric OCD . Neuropsychological neuroimaging data suggest OCD may arise dysfunction orbitofronto-striato-thalamocortical circuitry . Glutamate play crucial role regulation excitatory activity within circuit may involve etiopathogenesis OCD . If , agent reduce glutamatergic neurotransmission may provide unique antiobsessional benefit . Riluzole medication reduces glutamatergic activity . A small open-label trial suggest might reduce OCD severity among child adolescent . The investigation enroll 80 pediatric subject OCD include autistic spectrum disorder ( ASD ) OCD . The subject participate double-blind , placebo-controlled 12-week trial riluzole sole agent augmentation currently inadequate therapy . Following double-blind portion trial , subject may receive three month open-label treatment riluzole , clinically indicate . All subject follow regular interval one year baseline .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects may include study meet follow criterion : 1 . Male female subject , 7 17 year age . 2 . Male female subject childbearing potential must use medically accept mean contraception must remain abstinent . 3 . Each legal guardian must level understanding sufficient agree require test examination . Each legal guardian must understand nature study . Each legal guardian must consent study protocol . 4 . Subjects must fulfill DSMIV criterion ( OCD ) CYBOCS score great 20 . In doubleblind phase , subject enrol combined OCD ASD cohort must also meet DSMIV criterion Pervasive Developmental Disorder well OCD . 5 . Each subject already take medicine must take usually effective dos medicine demonstrate effective childhood OCD , must stable dose least six week , must newly recognize intolerable adverse effect medicine . Subjects currently take medication must adequate trial past least one medicine show effective symptom childhood OCD , must fail see improvement must intolerable adverse effect medicine . 6 . Subjects must able swallow capsule . EXCLUSION CRITERIA : Subjects exclude study follow reason : 1 . Presence psychotic symptom lifetime history schizophrenia , bipolar disorder , psychotic disorder , serious unstable psychiatric illness . Medically unstable due binging , purging , starvation . 2 . Judged clinically risk suicide ( suicidal ideation , severe depression , factor ) . Diagnosis DSMIV Major Depressive Disorder necessarily exclusion criterion . 3 . Disabling Tic Disorder require contraindicate medicine . 4 . Male female subject unwilling use effective contraception , female subject pregnant nursing . 5 . Serious unstable illness , include gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 6 . Renal hepatic dysfunction would interfere excretion metabolism riluzole evidence increase upper limit normal BUN/creatinine , twofold elevation upper limit normal serum transaminase ( ALT/SGPT , AST/SGOT ) , gamma glutamate ( GGT ) , bilirubin . 7 . Documented history hypersensitivity intolerance riluzole . 8 . DSMIV Substance Abuse Disorder within past 90 day Substance Dependence Disorder within past 5 year , use tobacco . 9 . Taking contraindicated drug . 10 . Unable swallow capsule . 11 . In addition , patient receive cognitivebehavior therapy period study . 12 . Abnormal EEG unless evaluated neurologist approve specialist protocol .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Glutamate Antagonist</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Basal Ganglia</keyword>
	<keyword>Neuropsychological</keyword>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>OCD</keyword>
	<keyword>Riluzole</keyword>
	<keyword>Rilutek</keyword>
</DOC>